Immunovant Sciences Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 2, 2019 and February 1, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 20, 2021.  If you are a shareholder who suffered a loss, click her...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the "Class Period"), of the important April 20, 2021 lead plaintiff deadline.

(1) NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the "Company") (NASDAQ: IMVT; HSACU; HSAC; and HSACW) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Immunovant securities between October 2, 2019 and Febr...

LOS ANGELES, CA / ACCESSWIRE / February 28, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor... | March 4, 2021